Kyohei Miyairi
Senior Researcher Ajinomoto Bio-Pharma Services
Seminars
Wednesday 9th September 2026
A Novel Scalable PSC Suspension Culture Media Optimized for Therapeutic Use
11:00 am
- Ajinomoto Group will introduce a novel animal origin‑free medium platform designed for robust PSC suspension culture across various cell lines while maintaining pluripotency and healthy aggregate morphology
- Our team will present data showing strong cell expansion, maintenance of the undifferentiated state, retained differentiation capacity, scalability across multiple culture reactors, and flexible labor‑saving culture schedules
